



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 248 844 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (48) Corrigendum issued on:
25.10.2006 Bulletin 2006/43
- (45) Date of publication and mention
of the grant of the patent:
30.08.2006 Bulletin 2006/35
- (21) Application number: **99967490.6**
- (22) Date of filing: **22.12.1999**
- (51) Int Cl.:
C12N 15/12 (2006.01) C07K 14/50 (2006.01)
A61K 38/18 (2006.01)
- (86) International application number:
PCT/US1999/030534
- (87) International publication number:
WO 2001/046416 (28.06.2001 Gazette 2001/26)

(54) **ANALOGS OF HUMAN BASIC FIBROBLAST GROWTH FACTOR**

ANALOGUE DES HUMANEN BASISCHEN FIBROBLASTEN-WACHSTUMSFACORS

ANALOGUES DU FACTEUR DE CROISSANCE FIBROBLASTIQUE BASIQUE HUMAIN

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI</p> <p>(43) Date of publication of application:
16.10.2002 Bulletin 2002/42</p> <p>(73) Proprietor: Ortho-McNeil Pharmaceutical, Inc.
Raritan, NJ 08869 (US)</p> <p>(72) Inventors:
• SPRINGER, Barry, A.
Wilmington, DE 19808 (US)
• PANTOLIANO, Michael, W.
Avondale, PA 19311 (US)</p> | <p>• SHARP, Celia, M.
Doylestown, PA 18901 (US)</p> <p>(74) Representative: Lee, Nicholas John et al
Kilburn & Strode,
20 Red Lion Street
London WC1R 4PJ (GB)</p> <p>(56) References cited:
EP-A- 0 363 675 EP-A- 0 510 662</p> <p>• KUSSTATSCHER, S. ET AL.: "Different Molecular
Forms of Basic Fibroblast Growth Factor (bFGF)
Accelerate Duodenal Ulcer Healing in Rats" J.
PHARMACOL. EXPERIM. THERAPEUTICS, vol.
275, 1995, pages 456-461, XP000930024</p> |
|---|---|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 248 844 B8